<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919436</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #4742</org_study_id>
    <nct_id>NCT02919436</nct_id>
  </id_info>
  <brief_title>Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery</brief_title>
  <acronym>DRIPS</acronym>
  <official_title>Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaineHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaineHealth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomization (1:1) of male patients, over age 50, undergoing elective spine surgery to&#xD;
      tamsulosin versus a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative urinary retention (POUR) is a common complication following certain surgical&#xD;
      operations. While much is known about the innervation and neural regulation of bladder&#xD;
      emptying and storage, the cause of urinary retention after surgery is not fully understood.&#xD;
      Early research has indicated that a small dose of tamsulosin (FlomaxÂ®), a commonly used&#xD;
      medication approved to treat urinary symptoms in men with benign prostatic hypertrophy, may&#xD;
      reduce the incidence of POUR. Urinary retention is a prevalent issue in patients undergoing&#xD;
      spinal surgery, leading to patient discomfort and prolonged length of stay. We hypothesize&#xD;
      that the use of perioperative tamsulosin in patients undergoing spinal surgery will decrease&#xD;
      the incidence of POUR.&#xD;
&#xD;
      The study is a prospective, double-blind, randomized, placebo-controlled trial. Subjects will&#xD;
      be randomized 1:1 to receive either oral tamsulosin 0.4 mg or placebo, taken once each&#xD;
      evening, beginning 5 days prior to surgery and continuing through the first postoperative&#xD;
      day. The primary endpoint is met when the patient is able to spontaneously empty their&#xD;
      bladder post-operatively, or needs to be catheterized with either a straight or indwelling&#xD;
      urinary catheter for post-operative urinary retention, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased rate of urinary catheterization</measure>
    <time_frame>Within 2 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>0-7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between preoperative post-void residual and post-op urinary retention</measure>
    <time_frame>Within 2 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of baseline IPSS (International Prostate Symptom Score) and post-op urinary retention</measure>
    <time_frame>Within 2 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Post-operative Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Active drug</description>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Flomax</other_name>
    <other_name>Flomaxtra</other_name>
    <other_name>Contiflo XL</other_name>
    <other_name>Urimax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose-filled capsules identical to active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male patient age 50 - 85 years&#xD;
&#xD;
          -  Undergoing elective spine surgery at least 5 days after enrollment&#xD;
&#xD;
          -  Preop visit done at office practice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on tamsulosin or other alpha-adrenergic blocking drug&#xD;
&#xD;
          -  Allergy to tamsulosin&#xD;
&#xD;
          -  Allergy to lactose&#xD;
&#xD;
          -  Serious or life-threatening allergy to sulfa drugs&#xD;
&#xD;
          -  Emergent procedure&#xD;
&#xD;
          -  History of spinal trauma, spinal infection or spinal cord tumor&#xD;
&#xD;
          -  Pre-existing indwelling urinary catheter&#xD;
&#xD;
          -  History of orthostatic hypotension or current orthostatic hypotension&#xD;
&#xD;
          -  History of prostate, urethral or bladder surgery&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Rughani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MaineHealth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MaineHealth</investigator_affiliation>
    <investigator_full_name>Anand Rughani, MD</investigator_full_name>
    <investigator_title>Neurosurgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Final results will be submitted to peer-reviewed journal for potential publication.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>October 15, 2021</submitted>
    <returned>November 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

